EU HTA Regulation: first joint clinical assessment completed (tovorafenib)

The new European benefit assessment has reached an important milestone: the first joint assessment, in which IQWiG was directly involved as the co-assessor, has been approved by the Member State Coordination Group on HTA. We are proud to have been directly involved right from the very first report. The collaboration with our Irish colleagues, and indeed at the European level as a whole, was excellent. Working together was very valuable; we were able to learn a great deal from one another and, at the same time, demonstrate that the new EU HTA process works. The subject of the first joint clinical assessment (JCA) was the anticancer drug tovorafenib for the treatment of paediatric low-grade glioma. For Germany, the Institute for Quality and